1. Latest News
  2. Submit Press Release
  1. PR Home
  2. Latest News
  3. Feeds
  4. Alerts
  5. Submit Free Press Release
  6. Journalist Account
  7. PRNewswire Distribution

Immune Response BioPharma, Inc. Is Granted U.S. Patent 8,053,197 for TCR Peptide Vaccine Technology

Immune Response BioPharma, Inc. announced today that it has received United States Patent Number 8,053,197 expanding coverage relating to its immune-based therapy for Treatment of Auto-Immune Diseases.

 
PRLog - May 11, 2012 - Immune Response BioPharma, Inc. Is Granted U.S. Patent 8,053,197 for TCR Peptide Vaccine Technology; Methods of Treating Auto-Immune Diseases



BriefingWire.com, 5/08/2012 - Immune Response BioPharma, Inc. Is Granted U.S. Patent 8,053,197 for TCR Peptide Vaccine Technology; Methods of Treating Auto-Immune Diseases
May 8, 2012

Immune Response BioPharma, Inc. announced today that it has received United States Patent Number 8,053,197 expanding coverage relating to its immune-based therapy for Treatment of Auto-Immune Diseases.

The recently issued patent has specific claims covering immunization utilizing TCR vaccines for Auto-Immune Diseases that are designed to synthesize the T cell receptor (TCR) Vbeta specific peptides and restore deficient FOXP3+ T cells in regards to immunizing patients directly with the TCR peptides. The patent also includes specific claims for Multiple Sclerosis including FOXP3+ Expression Technology which restores deficient pathogenic T-Regs in patients suffering from MS. The Company believes that vaccination with NeuroVax may inhibit & treat the disease-associated T cells that cause Multiple Sclerosis and prevent further damage in patients suffering from the disease with our proprietary vaccine formulation NeuroVax.

"This recent issuance of U.S. 8,053,197 is a key patent in that it extends key IP coverage including FOXP3+ Expression Technology related to the delivery and composition of NeuroVax with TCR peptide vaccines including the addition of estrogen to boost the vaccine potential in women suffering from MS." said Mr. David Buswell, IRBP Chief Executive Officer.

“The issuance of this patent to includes Treatment for Auto-Immune Diseases, TCR peptide vaccination technology, restoration of deficient FOXP3+ T-Regs utilizing the FOXP3+ Expression Technology for vaccination with our proprietary peptide formulations, the vaccine program serves to further strengthen our intellectual property position in the field of T cell receptor vaccine research in Rheumatoid Arthritis with RAVAX, in Psoriasis with ZORCELL and in Multiple Sclerosis with NeuroVax." Mr. David Buswell IRBP Chief Executive Officer.

Immune Response BioPharma, Inc. maybe found on the Worldwide Web @ www.immuneresponsebiopharma.com

--- End ---

Click to Share

Contact Email:
***@immuneresponsebiopharma.com Email Verified
Source:Immune Response BioPharma, Inc.
Phone:9172757931
Zip:10001
City/Town:New York City - New York - United States
Industry:Biotech, Business, Health
Tags:vaccines, MS, multiple sclerosis, drugs, immune response biopharma, TCR Peptides, patent
Shortcut:prlog.org/11873205
Disclaimer:   Issuers of the press releases are solely responsible for the content of their press releases. PRLog can't be held liable for the content posted by others.   Report Abuse

Latest Press Releases By “

More...

Trending News...



  1. SiteMap
  2. Privacy Policy
  3. Terms of Service
  4. Copyright Notice
  5. About
  6. Advertise
Like PRLog?
9K2K1K
Click to Share